Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease

Abroad (travel likely)RecruitingPHASE2

Conditions

Thyroid Eye Disease, TED · Graves Ophthalmopathy · Graves Orbitopathy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Contact: Study coordinator (Fangsen Xiao, MD) · xfs888@163.com · 13859955389
Contact: Study coordinator (Liying Wang, MM) · wlywly1979@163.com · +86-592-2137710
Contact: Principal Investigator (Fangsen Xiao, MD)

Study leads

Fangsen Xiao, MD
Principal Investigator
The First Affiliated Hospital of Xiamen University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Thyroid Eye Disease · Graves Orbitopathy · Endocrine System Diseases

Abroad (travel likely)RecruitingPHASE2, PHASE3

Miami, United States · Morgantown, United States

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

Thyroid Eye Disease, TED · Graves Ophthalmopathy

Abroad (travel likely)Recruiting

Taipei, Taiwan

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Thyroid Eye Disease

Abroad (travel likely)RecruitingPHASE1, PHASE2

Little Rock, United States · Newport Beach, United States

A Clinical Study of Cizutamig in Thyroid Eye Disease

Thyroid Eye Disease, TED

Abroad (travel likely)RecruitingPHASE1

Shanghai, China